nach oben

Erschienen in:

01.04.2014 | Original Article

The impact of dose/time modification in irinotecan- and oxaliplatin-based chemotherapies on outcomes in metastatic colorectal cancer

verfasst von: Goro Nakayama, Chie Tanaka, Keisuke Uehara, Naoki Mashita, Naomi Hayashi, Daisuke Kobayashi, Mitsuro Kanda, Suguru Yamada, Tsutomu Fujii, Hiroyuki Sugimoto, Masahiko Koike, Shuji Nomoto, Michitaka Fujiwara, Yuich Ando, Yasuhiro Kodera

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This study was designed to evaluate (1) the impact of relative dose intensity (RDI) on tumor response and survival outcomes and (2) the influence of dose reduction and schedule modification on outcomes in patients with metastatic colorectal cancer (mCRC).

Methods

Pooled datasets from two previous phase II trials of FOLFIRI (CCOG-0502; n = 36) and mFOLFOX6 (CCOG-0704; n = 30) in patients with mCRC were analyzed retrospectively. The RDIs of irinotecan and oxaliplatin were compared to response rate (RR), disease control rate (DCR), progression-free survival (PFS) and overall survival (OS). To assess the effects of dose reduction and schedule modification, the effects of dose index (DI) and time index (TI) on outcomes were evaluated.

Results

The median RDIs of irinotecan in FOLFIRI and oxaliplatin in mFOLFOX6 were 80 and 79 %, respectively. Higher RDI of irinotecan in FOLFIRI was associated with significant improvements in RR (65 vs. 6 %, p < 0.01), DCR (100 vs. 59 %, p < 0.01), PFS (9.9 vs. 5.6 months, p < 0.01) and OS (26.7 vs. 12.9 months, p = 0.01) and was the only independent factor associated with PFS [hazard ratio (HR) 8.48, p < 0.01). Higher RDI of oxaliplatin in FOLFOX was significantly associated with DCR (65 vs. 6 %, p < 0.01), and higher TI of oxaliplatin was the only independent factor associated with PFS (HR 2.74, p = 0.04).

Conclusion

RDIs of irinotecan and oxaliplatin affected clinical outcomes. Dose reductions in irinotecan, as indicated by DI, and time delays in oxaliplatin, as indicated by TI, were the only independent prognostic factors predicting PFS in patients receiving FOLFIRI and FOLFOX6, respectively.

Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343:905–914PubMedCrossRef

Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitkovic F, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL, Lévi F (2000) Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18:136–147PubMed

Grothey A, Sargent D, Goldberg RM, Schmoll HJ (2004) Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22:1209–1214PubMedCrossRef

Link BK, Budd GT, Scott S, Oncology Practice Pattern Study Working Group (2001) Delivering adjuvant chemotherapy to women with early-stage breast carcinoma: current patterns of care. Cancer 92:1354–1367PubMedCrossRef

Hryniuk WM (1988) The importance of dose intensity in the outcome of chemotherapy. Important Adv Oncol 121-141

Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C (1995) Adjuvant cyclophosphamide, methotrexate and fluorouracil in node positive breast cancer. New Engl J Med 14:901–916CrossRef

Loibl S, Skacel T, Nekljudova V, Lück HJ, Schwenkglenks M, Brodowicz T, Zielinski C, von Minckwitz G (2011) Evaluating the impact of relative total dose intensity (RTDI) on patients’ short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis. BMC Cancer 11:131PubMedCentralPubMedCrossRef

Epelbaum R, Haim N, Ben-Shahar M, Ron Y, Cohen Y (1988) Dose-intensity analysis for CHOP chemotherapy in diffuse aggressive large cell lymphoma. Isr J Med Sci 24:533–538PubMed

Kwak LW, Halpern J, Olshen RA, Horning SJ (1990) Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol 8:963–977PubMed

10.

Luciani A, Bertuzzi C, Ascione G, Di Gennaro E, Bozzoni S, Zonato S, Ferrari D, Foa P (2009) Dose intensity correlate with survival in elderly patients treated with chemotherapy for advanced non-small cell lung cancer. L Cancer 66:94–96CrossRef

11.

Repetto L, Pace M, Mammoliti S, Bruzzone M, Chiara S, Oliva C, Guido T, Conte PF, Campora E, Rubagotti A et al (1993) The impact of received dose intensity on the outcome of advanced ovarian cancer. Eur J Cancer 29:181–184CrossRef

12.

Fauci JM, Whitworth JM, Schneider KE, Subramaniam A, Zhang B, Frederick PJ, Kilgore LC, Straughn JM Jr (2011) Prognostic significance of the relative dose intensity of chemotherapy in primary treatment of epithelial ovarian cancer. Gynecol Oncol 122:532–535PubMedCrossRef

13.

Hryniuk WM, Figueredo A, Goodyear M (1987) Applications of dose intensity to problems in chemotherapy of breast and colorectal cancer. Semin Oncol 14:3–11PubMed

14.

Cascinu S, Fedeli A, Luzi FS, Catalano G (1991) 5-Fluorouracil dose intensity increase in 5-fluorouracil and leucovorin combination: results of a phase II study. J Chemother 3:51–54PubMed

15.

Maindrault-Goebel F, de Gramont A, Louvet C, André T, Carola E, Gilles V, Lotz JP, Tournigand C, Mabro M, Molitor JL, Artru P, Izrael V, Krulik M (2000) Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-h 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology multidisciplinary research group (GERCOR). Ann Oncol 11:1477–1483PubMedCrossRef

16.

Nakayama G, Kodera Y, Yokoyama H, Okuda N, Watanabe T, Tanaka C, Iwata N, Ohashi N, Koike M, Fujiwara M, Nakao A (2011) Modified FOLFOX6 with oxaliplatin stop-and-go strategy and oral S-1 maintenance therapy in advanced colorectal cancer: CCOG-0704 study. Int J Clin Oncol 16:506–511PubMedCrossRef

17.

Coldman AJ, Goldie JH (1987) Impact of dose-intense chemotherapy on the development of permanent drug resistance. Semin Oncol 14:29–33PubMed

18.

Norton L (1997) Evolving concepts in the systemic drug therapy of breast cancer. Semin Oncol 24:S10-3–S10-10

19.

Raymond E, Lawrence R, Izbicka E, Faivre S, Von Hoff DD (1998) Activity of oxaliplatin against human tumor colony-forming units. Clin Cancer Res 4:1021–1029PubMed

20.

Yamashita K, Nagashima F, Fujita K, Yamamoto W, Endo H, Miya T, Narabayashi M, Kawara K, Akiyama Y, Ando Y, Ando M, Sasaki Y (2011) Phase I/II study of FOLFIRI in Japanese patients with advanced colorectal cancer. Jpn J Clin Oncol 41:204–209PubMedCrossRef

21.

Sunakawa Y, Ichikawa W, Fujita K, Nagashima F, Ishida H, Yamashita K, Mizuno K, Miwa K, Kawara K, Akiyama Y, Araki K, Yamamoto W, Miya T, Narabayashi M, Ando Y, Hirose T, Saji S, Sasaki Y (2011) UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer. Cancer Chemother Pharmacol 68:279–284PubMedCrossRef

Titel: The impact of dose/time modification in irinotecan- and oxaliplatin-based chemotherapies on outcomes in metastatic colorectal cancer
verfasst von: Goro Nakayama
Chie Tanaka
Keisuke Uehara
Naoki Mashita
Naomi Hayashi
Daisuke Kobayashi
Mitsuro Kanda
Suguru Yamada
Tsutomu Fujii
Hiroyuki Sugimoto
Masahiko Koike
Shuji Nomoto
Michitaka Fujiwara
Yuich Ando
Yasuhiro Kodera
Publikationsdatum: 01.04.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 4/2014
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-014-2416-x

Springer Medizin

The impact of dose/time modification in irinotecan- and oxaliplatin-based chemotherapies on outcomes in metastatic colorectal cancer